Vor Biopharma (NASDAQ:VOR) Shares Up 8.3% – Time to Buy?

Vor Biopharma Inc. (NASDAQ:VOR) shares were up 8.3% during mid-day trading on Wednesday . The company traded as high as $15.32 and last traded at $15.2650. Approximately 392,838 shares were traded during mid-day trading, a decline of 60% from the average daily volume of 986,901 shares. The stock had previously closed at $14.10.

Analysts Set New Price Targets

A number of brokerages recently issued reports on VOR. Wall Street Zen lowered shares of Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Wells Fargo & Company began coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They set an “overweight” rating and a $30.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Vor Biopharma in a report on Monday, May 18th. Wedbush increased their price target on shares of Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Finally, Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $42.25.

Vor Biopharma Trading Up 10.2%

The business has a 50-day moving average of $15.07 and a 200-day moving average of $13.68.

Vor Biopharma (NASDAQ:VOR) last posted its earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. Analysts predict that Vor Biopharma Inc. will post -2.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Vor Biopharma

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 589,257 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63. Following the sale, the director owned 4,555,741 shares of the company’s stock, valued at $75,579,743.19. The trade was a 11.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders have sold 3,002,903 shares of company stock worth $49,412,176. Company insiders own 0.45% of the company’s stock.

Institutional Investors Weigh In On Vor Biopharma

Several institutional investors and hedge funds have recently modified their holdings of VOR. China Universal Asset Management Co. Ltd. purchased a new position in Vor Biopharma during the 4th quarter valued at about $36,000. Squarepoint Ops LLC acquired a new position in shares of Vor Biopharma in the third quarter valued at approximately $230,000. Bank of America Corp DE grew its holdings in shares of Vor Biopharma by 679.3% in the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after purchasing an additional 4,144 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after buying an additional 5,058 shares during the period. Finally, Bridgeway Capital Management LLC acquired a new stake in Vor Biopharma during the 3rd quarter worth approximately $304,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).